In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Topical glucocorticoids still belong to the most important medications available in dermatotherapy. The clinical use of topical glucocorticoids, however, nowadays is limited by the fear of side-effects both systemic and local, especially skin atrophy. The purpose of this study was to assess the atrophogenicity potential of newly developed topical glucocorticoids which were said to show an increased benefit-risk ratio. The test preparations comprised mometasone furoate, the corresponding vehicle, prednicarbate and hydrocortisone. They were applied once or twice daily for 6 weeks in healthy volunteers. Skin thickness was assessed weekly by using high frequency pulsed ultrasound. Clinically, none of the volunteers showed any sign of overt skin atrophy. Skin thickness, however, was reduced to a certain extent with all trial preparations including the base preparation. As to be expected from previous experiments the results for hydrocortisone and prednicarbate did not differ significantly from the ones for the base preparation. Interestingly, the same applied to mometasone furoate. These findings, together with the other available data, give evidence of an increased benefit-risk ratio as compared to previous medium potent topical glucocorticoids. This might be of particular interest facing psoriasis vulgaris where an antiproliferative activity of a drug is needed.